Clinical trials: psoriasis
Psoriasis
Tilrdakizumab Almirall
Define the mechanisms underlying the short- and the long-lasting effects of IL-23 targeting in plaque PsO, by characterizing the longitudinal effects of IL-23 inhibition on the ratio of Trm/Treg cells in the skin of moderate to…
- Trial name
- NCT07244744
- Testing
- Tildrakizumab
- Where
- Germany
- Volunteers
- 3 people
- Sponsor
- University Hospital Schleswig-Holstein
Generalized Pustular Psoriasis (GPP)
Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)
This is a phase II, multicenter, double-blind, randomized, placebo parallel-controlled clinical trial to evaluate the efficacy and safety of HB0034 in patients with generalized pustular psoriasis (GPP) presenting with an acute…
- Trial name
- NCT06231381
- Testing
- HB0034
- Where
- 2 sites in China
- Volunteers
- 33 people
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
Psoriasis
A Study of Ixekizumab in Participants With Plaque Psoriasis
This study is known as a "drug interaction study." The purpose is to learn about how ixekizumab may affect the blood levels of a mixture of commonly used drugs (caffeine, omeprazole, warfarin, dextromethorphan, and midazolam)…
- Trial name
- NCT02993471
- Testing
- Drug Cocktail, Ixekizumab
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Palmoplantar Pustulosis (PPP)
A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar Pustulosis
What's the problem? Palmoplantar pustulosis (PPP) is a long-term skin condition that mainly affects the palms of hands and soles of feet.
- Trial name
- NCT07270003
- Testing
- Ivarmacitinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xijing Hospital
Moderate to Severe Psoriasis
Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis
Multicentre, open label, phase III study. Subjects with moderate to severe psoriasis were given efalizumab subcutaneously once per week for the 12-week treatment period.
- Trial name
- NCT00442650
- Testing
- Efalizumab
- Where
- Switzerland
- Sponsor
- Merck KGaA, Darmstadt, Germany
Psoriasis Vulgaris
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
A phase 3 trial comparing the efficacy and safety of LEO 90100 aerosol foam with the aerosol foam vehicle used twice weekly as long-term maintenance therapy in subjects with psoriasis vulgaris.
- Trial name
- NCT02899962
- Testing
- LEO 90100 aerosol foam, LEO 90100 aerosol foam vehicle
- Where
- 58 sites in United States, Canada and 4 more
- Volunteers
- 722 people
- Sponsor
- LEO Pharma
Plaque Psoriasis
A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
Subjects with a clinical diagnosis of plaque psoriasis with 10% to 20% of body surface area affected will be enrolled in the study.
- Trial name
- IDP-118 (NCT01670513)
- Testing
- IDP-118 Low Strength, IDP-118 High Strength
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Dow Pharmaceutical Sciences
Rheumatoid Arthritis
CorEvitas Rheumatoid Arthritis (RA) Drug Safety & Effectiveness Registry
This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for RA in a cohort of patients cared for by rheumatologists across North…
- Trial name
- NCT01402661
- Where
- United States
- Volunteers
- 91,758 people
- Sponsor
- CorEvitas
Plaque Psoriasis
Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis
This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in adults with plaque psoriasis.
- Trial name
- NCT04042103
- Testing
- Tapinarof cream, 1%
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Organon and Co
Diabetes, Psoriasis
Diabetes and Psoriasis
Patients with psoriasis will be evaluated. The investigators will collect personal history, concomitant diseases and in particular the presence of type 2 diabetes mellitus, impaired fasting glucose and impaired glucose…
- Trial name
- NCT02366273
- Testing
- PASI and HOMA index
- Where
- Italy
- Volunteers
- 425 people
- Sponsor
- University of Pavia
Psoriasis
Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects
This is a phase 1, multi-center, open-label, drug-drug interaction (DDI) and PK study in subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT01937260
- Testing
- Brodalumab
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 31 people
- Sponsor
- Bausch Health Americas, Inc.
Psoriasis Vulgaris
Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris
The purpose of this study is to evaluate the effectiveness of 3 dose strengths of CT327 ointment (0.05%, 0.1% and 0.05% w/w) compared to a placebo, when applied twice daily for up to 8 weeks, to the psoriatic plaques of patients…
- Trial name
- NCT01465282
- Testing
- CT327 0.05%, CT327 0.1%, CT327 0.5%
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 160 people
- Sponsor
- Creabilis SA
Atopic Dermatitis, Psoriasis
Clinical, Psychological and Genetic Characteristics in Dermatological Patients
Atopic dermatitis (AD) and psoriasis (PS) are chronic, relapsing dermatological disorders with a high rate of psychiatric co-morbid pathology represented with depression.
- Trial name
- NCT03831646
- Where
- Kazakhstan
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Astana Medical University
Psoriatic Arthritis, Psoriasis
Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthritis
This exploratory study will be used to identify questions that will be part of a new QoL questionnaire for patients with psoriasis and psoriatic arthritis and to determine the sample size needed for its validation.
- Trial name
- NCT01139918
- Where
- 10 sites in Canada
- Volunteers
- 105 people
- Sponsor
- Innovaderm Research Inc.
Psoriasis
A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)
This is a study of the safety and efficacy of ustekinumab (CNTO 1275) in adolescent patients with moderate to severe psoriasis.
- Trial name
- NCT01090427
- Testing
- Ustekinumab - Half-Standard Dosage, Ustekinumab - Standard Dosage
- Where
- 50 sites in Belgium, Canada and 8 more
- Volunteers
- 110 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
Trial to Evaluate Topical C-82 in a Psoriasis Plaque Test
Evaluate the effects of topical C-82 in a psoriasis plaque test.
- Trial name
- NCT02432027
- Testing
- C-82 Topical Gel, 1%, Daivonex cream, Diprosis gel
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- Prism Pharma Co., Ltd.
Rheumatoid Arthritis, Spondyloarthritis
The Norwegian Drug Monitoring Study
Infliximab and other TNF-inhibitors have revolutionised the treatment of several immunological inflammatory diseases. Still, more than half of the patients either do not respond sufficiently to infliximab therapy or loose…
- Conditions
- Rheumatoid Arthritis, Spondyloarthritis, Ankylosing Spondylitis, Crohn Disease
- Trial name
- NOR-DRUM (NCT03074656)
- Testing
- Therapeutic drug monitoring, Standard care
- Where
- 21 sites in Norway
- Volunteers
- 611 people
- Sponsor
- Diakonhjemmet Hospital
Palmoplantar Pustulosis
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of adult participants with mild to severe palmoplantar pustulosis…
- Trial name
- NCT07013201
- Testing
- Delgocitinib cream, Vehicle cream
- Where
- 40 sites in United States, Canada and 3 more
- Volunteers
- 135 people
- Sponsor
- LEO Pharma
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Atopic Dermatitis, Plaque Psoriasis
Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis
This study is being conducted to provide data on efficacy, safety, tolerability and PK of PF-07038124 ointment versus vehicle control in the treatment of mild to moderate AD and mild to moderate plaque psoriasis.
- Trial name
- EMPORIA (NCT04664153)
- Testing
- PF-07038124 ointment, Vehicle ointment
- Where
- 29 sites in United States, Australia and 2 more
- Volunteers
- 104 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.